Chemotherapy-Induced Cardiomyopathy Monica Abraham Intern Mentor Atholton High School Mentor: Lili Barouch, M.D. Johns Hopkins Cardiology Columbia Medical Campus
Preview Research Question Anthracyclines Chemotherapy-Induced Cardiomyopathy Risk Factors My Research Conclusion
Research Question Which risk factor makes patients most likely to develop chemotherapy-induced cardiomyopathy? Research Design: Causal-Comparative Terms: -chemotherapy: the treatment of cancer by the use of chemical substances -cardiomyopathy: the deterioration of the heart muscle -anthracycline: common type of breast cancer chemotherapy drug -myocyte: muscle cell
Anthracyclines Chemotherapy agents Commonly treat breast cancer and lymphomas Can cause cardiomyopathy Myocyte damage Production of toxic radicals Increase in oxidative stress Lipid peroxidation Vacuolation Myocyte replacement by fibrous tissue
Chemotherapy-Induced Cardiomyopathy Symptoms palpitations, shortness of breath, chest pain, fatigue Acute Cardiovascular Complications Short-term Arrythmias Chronic Cardiotoxicity Clinical heart failure May be a link between acute and chronic cardiotoxicity
Risk Factors Cumulative dose Age Other cardiotoxic chemotherapy agents Radiation History of CVD
My Research Purpose is to identify most prevalent risk factor Review charts of prior and current patients of Dr. Barouch to study patients’ histories Be able to ascertain most common risk factor Patients with that risk factor can then consider their options
Conclusion Certain chemotherapy drugs, such as anthracyclines, damage myocardial function Cardiomyopathy can result Important to determine which risk factors are most detrimental Prevention medication and screening can help reduce risk of cardiomyopathy
Works Cited Barouch, Lili. Personal interview. 23 Oct. 2013. Gharib, M. I., and A. K. Burnett. "Chemotherapy-induced Cardiotoxicity: Current Practice and Prospects of Prophylaxis." European Journal of Heart Failure (2002). Oxford Journals. Web. 19 Oct. 2013. Hare, Joshua M. "The Etiologic Basis of Congestive Heart Failure." Atlas of Heart Failure: Cardiac Function and Dysfunction. 3rd ed. 2002. Print. Katz, Arnold M. "Molecular and Cellular Basis of Contraction." Atlas of Heart Failure: Cardiac Function and Dysfunction. Ed. Wilson S. Colucci. 3rd ed. 2002. Print. Singal, Pawan K., and Natasha Iliskovic. "Doxorubicin-Induced Cardiomyopathy." New England Journal of Medicine (1998). Google Scholar. Web. 19 Oct. 2013.